Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. develops artificial intelligence medical diagnostics for wound care, with the DeepView System as its principal platform for burn-wound assessment. DeepView combines multispectral imaging with a proprietary AI algorithm to evaluate the healing potential of burn wounds and provide a binary prediction on whether tissue is likely to heal within a specified period.
Recurring news about Spectral AI covers DeepView presentations at burn-care medical meetings, BARDA funding for burn imaging technology, FDA De Novo 510(k) activity, financial results, commercialization preparation, stockholder meetings and executive appointments. Company updates also describe research and development revenue tied to government-supported development work and governance matters associated with its Nasdaq-listed common stock.
Spectral AI (NASDAQ: MDAI) reported third-quarter 2025 results for the period ended September 30, 2025, highlighting Q3 R&D revenue of $3.8 million and YTD revenue of $15.6 million. Cash improved to $10.5 million as of Sept 30, 2025 (flat vs Q2 2025; up from $3.7M in Q3 2024). The company recorded a Q3 net loss of $3.6 million versus $1.5 million a year earlier, driven by a 54% decline in R&D revenue after its June De Novo submission to the FDA.
After quarter close (Oct 22, 2025) Spectral entered a securities purchase agreement raising ~$7.6 million gross via common shares, warrants and pre-funded warrants. Full-year revenue guidance was lowered from $21.5M to $18.5M, citing BARDA timing and a U.S. government shutdown impact.
Spectral AI (Nasdaq: MDAI) will report third quarter financial results for the period ended September 30, 2025 on Tuesday, November 11, 2025 after market close. The company will host a conference call the same day at 5:00 PM ET to discuss results. Investors can join by dialing 833-630-1956 (U.S.) or 412-317-1837 (International), or via a simultaneous webcast available on the company’s Investor Relations Events & Presentations page at https://investors.spectral-ai.com/news-events/events.
Spectral AI (Nasdaq: MDAI) priced a $7.6 million offering on October 23, 2025 to fund expansion of its DeepView® System. The financing includes the issuance of 4,000,000 shares of common stock and pre-funded warrants at $1.90 per share, plus corresponding warrants with an exercise price of $2.51 per share.
The company said proceeds will support continued development, broaden clinical indications, and prepare for commercial readiness in 2026, while maintaining support for its BARDA Project BioShield contract. Northland Capital Markets served as exclusive placement agent and Reed Smith served as counsel.
Spectral AI (Nasdaq: MDAI), a medical diagnostics company specializing in AI-powered wound care solutions, has been recognized on TIME's World's Top HealthTech Companies 2025 list. The prestigious ranking, published on September 18, 2025, features 400 leading healthcare technology innovators selected from thousands of companies globally.
Companies were evaluated based on three key criteria: financial performance, reputation analysis, and online engagement. The recognition highlights Spectral AI's progress in developing their DeepView technology as they work towards global commercialization of their AI-based predictive wound care solutions.
Spectral AI (NASDAQ: MDAI) showcased its DeepView® System at the European Burns Association (EBA) Congress in Berlin, Germany. The AI-powered medical diagnostics technology was featured in six key presentations and posters from various international medical institutions, primarily focusing on burn wound assessment and treatment.
Notable presentations included studies from the North Bristol NHS Trust, Louisiana State University, and the Royal Victoria Infirmary, demonstrating the system's application in real-world settings. The research highlighted DeepView's capabilities in burn depth assessment, wound healing potential prediction, and patient experience measurements using AI-enhanced multispectral imaging.
Spectral AI (NASDAQ:MDAI), an AI medical diagnostics company focused on wound care, reported its Q2 2025 financial results. The company achieved $5.1 million in R&D revenue for Q2 and $11.8 million for H1 2025. A significant milestone was reached with the completion of their De Novo FDA application submission for the DeepView System in June 2025.
Financial highlights include a cash position of $10.5 million, up from $5.2 million in December 2024, supported by a $15 million debt financing agreement with Avenue Capital Group. The company reported a Q2 net loss of $7.9 million, primarily due to warrant liability adjustments. Gross margin was 45.2%, slightly down from 46.6% in Q2 2024. Management reaffirmed full-year 2025 revenue guidance of $21.5 million.
Spectral AI (NASDAQ: MDAI), a company specializing in AI-driven medical diagnostics for wound care through their DeepView® System, has scheduled its Q2 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 5:00 PM ET on the same day to discuss the results. Investors can participate by dialing 833-630-1956 (U.S.) or 412-317-1837 (International). A simultaneous webcast will be available on the company's investor relations website.
Spectral AI (NASDAQ: MDAI) has submitted a De Novo 510k marketing clearance application to the FDA for its DeepView® System, a breakthrough medical device designed for burn care settings. The DeepView System, which received FDA Breakthrough Device Designation in 2018, combines multi-spectral imaging with AI algorithms to predict burn wound healing potential.
The system provides non-invasive healing predictions on the day of injury and up to 7 days post-injury, enabling clinicians to make earlier and more informed treatment decisions. The De Novo regulatory pathway was chosen due to the technology's novel nature, as no predicate device exists in the U.S. market.
The development has been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA through multiple contract awards since 2013, with the current contract number being 75A50123C00049.